aml hub

Virtual Lymphoma Hub Satellite Symposium

ESH How to Diagnose and Treat: Lymphoma
November 8, 2020 | 15:50 CET

How I treat relapsed/refractory disease – DLBCL and CLL

During the virtual Lymphoma Hub Satellite Symposium, an international panel of 5 experts will provide an overview of the different treatment approaches for patients with relapsed/refractory disease.

While frontline treatment approaches in non-Hodgkin lymphomas and CLL have made tremendous progress, the treatment of patients with relapsed/refractory disease can be a challenge.

The clinical situation based on past treatment history and disease features are quite variable. Often, these patients present with characteristics that make the disease difficult to treat. Factors like chemo-resistance, exhausted bone marrow reserve or reduced performance status pose special challenges to physicians and require a very personalized approach to treatment strategy.

This overview will highlight the latest advances in the field, special treatment challenges and regional differences to help physicians make the best treatment decision possible for patients with relapsed/refractory disease in areas with a high unmet medical need.

Agenda

How I treat relapsed/refractory disease – DLBCL and CLL

Sunday November 8, 2020 | 15:50 CET

Welcome and introductions

Case 1: Patient with R/R DLBCL

  • US perspective - Kieron Dunleavy
  • European perspective - Marie-José Kersten

Case 2: Patient with R/R CLL

  • Latin American perspective - Astrid Pavlovsky
  • European perspective - Francesc Bosch

All

16:35

Q&A and round table discussion

Summary and conclusions

16:50

Meeting concludes

Conference

Join the conversation – the virtual Lymphoma Hub Satellite Symposium will take place at the ESH How to Diagnose and Treat: Lymphoma virtual conference.

Location

This site uses cookies in order for us to continually develop and improve the service we can offer you. Read more